Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma.

Muhitch JB, Hoffend NC, Azabdaftari G, Miller A, Bshara W, Morrison CD, Schwaab T, Abrams SI.

J Immunother Cancer. 2019 Jun 20;7(1):155. doi: 10.1186/s40425-019-0630-0.

2.

Storage Conditions and Immunoreactivity of Breast Cancer Subtyping Markers in Tissue Microarray Sections.

Omilian AR, Zirpoli GR, Cheng TD, Yao S, Stein L, Davis W, Head KL, Nair P, Khoury T, Ambrosone CB, Bshara W.

Appl Immunohistochem Mol Morphol. 2019 Jun 12. doi: 10.1097/PAI.0000000000000756. [Epub ahead of print]

PMID:
31205070
3.

TP53 Status as a Determinant of Pro- versus Anti-tumorigenic Effects of Estrogen Receptor-beta in Breast Cancer.

Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Borresen-Dale AL, Creighton CJ, Park JH, Konduri SD, Mukhopadhyay A, Caradori A, Omilian A, Bshara W, Kaipparettu BA, Das GM.

J Natl Cancer Inst. 2019 Apr 16. pii: djz051. doi: 10.1093/jnci/djz051. [Epub ahead of print]

PMID:
30990221
4.

Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer.

Kumar R, Bhat TA, Walsh EM, Chaudhary AK, O'Malley J, Rhim JS, Wang J, Morrison CD, Attwood K, Bshara W, Mohler JL, Yadav N, Chandra D.

Cancer Res. 2019 Apr 1;79(7):1353-1368. doi: 10.1158/0008-5472.CAN-18-2383. Epub 2019 Feb 14.

PMID:
30765600
5.

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C.

J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3.

6.

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.

Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C.

J Immunother Cancer. 2019 Jan 24;7(1):18. doi: 10.1186/s40425-018-0489-5.

7.

KLF9-dependent ROS regulate melanoma progression in stage-specific manner.

Bagati A, Moparthy S, Fink EE, Bianchi-Smiraglia A, Yun DH, Kolesnikova M, Udartseva OO, Wolff DW, Roll MV, Lipchick BC, Han Z, Kozlova NI, Jowdy P, Berman AE, Box NF, Rodriguez C, Bshara W, Kandel ES, Soengas MS, Paragh G, Nikiforov MA.

Oncogene. 2019 May;38(19):3585-3597. doi: 10.1038/s41388-019-0689-6. Epub 2019 Jan 21.

PMID:
30664687
8.

Analysis of mutations in primary and metastatic synovial sarcoma.

Xing Z, Wei L, Jiang X, Conroy J, Glenn S, Bshara W, Yu T, Pao A, Tanaka S, Kawai A, Choi C, Wang J, Liu S, Morrison C, Yu YE.

Oncotarget. 2018 Dec 7;9(96):36878-36888. doi: 10.18632/oncotarget.26416. eCollection 2018 Dec 7.

9.

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.

Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS.

J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8.

10.

Frequency of breast cancer subtypes among African American women in the AMBER consortium.

Allott EH, Geradts J, Cohen SM, Khoury T, Zirpoli GR, Bshara W, Davis W, Omilian A, Nair P, Ondracek RP, Cheng TD, Miller CR, Hwang H, Thorne LB, O'Connor S, Bethea TN, Bell ME, Hu Z, Li Y, Kirk EL, Sun X, Ruiz-Narvaez EA, Perou CM, Palmer JR, Olshan AF, Ambrosone CB, Troester MA.

Breast Cancer Res. 2018 Feb 6;20(1):12. doi: 10.1186/s13058-018-0939-5.

11.

Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).

Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2018 Jul 1;110(7):734-742. doi: 10.1093/jnci/djx260.

12.

Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors.

Conroy JM, Pabla S, Glenn ST, Burgher B, Nesline M, Papanicolau-Sengos A, Andreas J, Giamo V, Lenzo FL, Hyland FCL, Omilian A, Bshara W, Qin M, He J, Puzanov I, Ernstoff MS, Gardner M, Galluzzi L, Morrison C.

J Mol Diagn. 2018 Jan;20(1):95-109. doi: 10.1016/j.jmoldx.2017.10.001. Epub 2017 Oct 20.

PMID:
29061374
13.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5. Erratum in: Cell. 2018 Aug 9;174(4):1033.

14.

Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods.

Khoury T, Zirpoli G, Cohen SM, Geradts J, Omilian A, Davis W, Bshara W, Miller R, Mathews MM, Troester M, Palmer JR, Ambrosone CB.

Am J Clin Pathol. 2017 Aug 1;148(2):108-118. doi: 10.1093/ajcp/aqx053.

15.

A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.

Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy LK, Warren GW, Bshara W, Odunsi K, Matsuzaki J, Abrams SI, Schwaab T, Muhitch JB.

Clin Cancer Res. 2017 Sep 1;23(17):5055-5065. doi: 10.1158/1078-0432.CCR-16-2946. Epub 2017 Jun 19.

16.

Prognostic value of histone chaperone FACT subunits expression in breast cancer.

Attwood K, Fleyshman D, Prendergast L, Paszkiewicz G, Omilian AR, Bshara W, Gurova K.

Breast Cancer (Dove Med Press). 2017 May 3;9:301-311. doi: 10.2147/BCTT.S126390. eCollection 2017.

17.

Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Grabosch S, Tseng G, Edwards RP, Lankes HA, Moore K, Odunsi K, Vlad A, Ma T, Strange M, Brozick J, Lugade A, Omilian A, Bshara W, Stuckey AR, Walker JL, Birrer M.

Gynecol Oncol. 2017 Jul;146(1):137-145. doi: 10.1016/j.ygyno.2017.04.008. Epub 2017 May 5.

18.

P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.

Babagana M, Johnson S, Slabodkin H, Bshara W, Morrison C, Kandel ES.

Mol Carcinog. 2017 May;56(5):1515-1525. doi: 10.1002/mc.22611. Epub 2017 Feb 23.

19.

A four gene signature predictive of recurrent prostate cancer.

Komisarof J, McCall M, Newman L, Bshara W, Mohler JL, Morrison C, Land H.

Oncotarget. 2017 Jan 10;8(2):3430-3440. doi: 10.18632/oncotarget.13837.

20.

Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing.

Paluch BE, Glenn ST, Conroy JM, Papanicolau-Sengos A, Bshara W, Omilian AR, Brese E, Nesline M, Burgher B, Andreas J, Odunsi K, Eng K, He J, Qin M, Gardner M, Galluzzi L, Morrison CD.

Oncotarget. 2017 Jan 10;8(2):3197-3205. doi: 10.18632/oncotarget.13691.

Supplemental Content

Loading ...
Support Center